best glp-1 drugs for weight loss usa 2025 from the Gray Market Perspectives from employers on the

Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients

Its naturally present in a healthy gut, but its levels decline with poor diet, stress, antibiotics, aging, and other modern lifestyle factors

To minimise confounding effects, we compared GLP-1RAs with second- or third-line glucose-lowering medications

These include a dual agonist combining glucagon and GLP-1 activity and another with GIP and GLP-1 activity

The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)